Not eps related; but, MRK's Arcoxia up for approval. More volatility ahead. "<A HREF="http://www.nytimes.com/imagepages/2004/10/03/business/20041003_VIOX_GRAPH.html" target="_blank">http://www.nytimes.com/imagepages/2004/10/03/business/20041003_VIOX_GRAPH.html</A> "